Viking Therapeutics stock jumped higher last year because it looks like a dual GLP-1/GIP agonist it's developing could ...

CEO Brian Lian highlighted 2024 as an exceptionally busy year, with successful results from four studies, including the Phase 2 VENTURE trial for subcutaneous VK2735, which demonstrated up to 14.7% ...

Viking is pursuing VK2809, an experimental treatment for metabolic dysfunction-associated steatohepatitis (MASH), outside VK2735. A Phase 2b VOYAGE study showed that VK2809 dramatically lowers ...

In early 2024, Viking announced positive top-line results from its Phase 2 VENTURE study of VK2735 in obesity. The VENTURE trial successfully achieved its primary and all secondary endpoints ...

Initiation of Phase 3 Studies for Subcutaneous VK2735 ... promising data, Viking is currently planning to file an IND application for this program later this year. Viking Therapeutics, Inc ...

Citi analyst David Lebowitz initiated coverage of Viking Therapeutics (VKTX) with a Neutral rating and $38 price target Viking’s VK2735 is an “intriguing potential blockbuster,” with its GLP ...

The excitement surrounding Viking Therapeutics (NASDAQ ... company would acquire it for its promising GLP-1 treatment, VK2735 -- but that doesn't appear to be happening. And with a growing ...